OncoCyte Reports Positive Analytical Validation Study Results of DetermaVu™ Lung Cancer Diagnostic Test
18 sept. 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the early detection of...
OncoCyte to Present Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer Symposium
11 sept. 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today...
OncoCyte Receives CLIA Certification for its Cancer Diagnostics Laboratory
07 sept. 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that its...
Seasoned Diagnostics Sales Executive Joins OncoCyte to Drive Commercialization and Future Sales Initiatives of DetermaVu™, the Company’s Novel Liquid Biopsy Lung Cancer Diagnostic
05 sept. 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE AMERICAN:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that Michael...
OncoCyte Confirms Launch Plans for Lung Cancer Diagnostic Test; Reports Progress Toward CLIA Lab Licensing and Second Quarter 2017 Financial Results
14 août 2017 16h10 HE
|
OncoCyte Corporation
- Introduces Lung Cancer Diagnostic Branding- -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel,...
OncoCyte Latest Lung Cancer Diagnostic Test Data Accepted for Slide Presentation at CHEST 2017 Annual Meeting
07 août 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests to support the early detection of cancer, announced today that data...
OncoCyte to Report Second Quarter Financial Results on August 14, 2017
26 juil. 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that...
OncoCyte Receives $5.74 Million in Proceeds from Exercise of Warrants
25 juil. 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of...
OncoCyte Analytical Validation Study of its Lung Cancer Diagnostic Test Confirms Previously Published Results
24 juil. 2017 07h00 HE
|
OncoCyte Corporation
- Abstract to Present Complete Study Findings Submitted to a Scientific Conference - - Final Stage of Development Commences- ALAMEDA, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation...
OncoCyte Corporation Added to Russell 3000® Index and Russell 2000® Index
26 juin 2017 07h00 HE
|
OncoCyte Corporation
ALAMEDA, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, has been...